Citius Pharmaceuticals: FDA accepts BLA resubmission of LYMPHIR

Citius Pharmaceuticals announced that the U.S. FDA has accepted the resubmission of the company’s Biologics License Application for LYMPHIR, an IL-2-based immunotherapy for the treatment of patients with relapsed or refractory cutaneous T-cell lymphoma after at least one prior systemic therapy. The FDA has assigned a PDUFA goal date of August 13, 2024.